BioSpace News Archive

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference, taking place virtually on February 1, 2024.

ReLive is proud to announce that the Health Sciences Authority (HSA), Singapore’s highest health authority, has granted New Drug Application (NDA) approval for SpheChon 10-70 spheroids/cm² in December 2023, marking the country’s first cell therapy product for cartilage repair in its history.

Sagimet Biosciences Inc. announced the commencement of an underwritten public offering of 9,000,000 shares of its Series A common stock.

SAB Biotherapeutics, Inc. announced that it received notice from The Nasdaq Stock Market LLC on January 23, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on the Nasdaq Capital Market.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first pediatric patient has been dosed in clinical trial with its second generation pan-TRK inhibitor zurletrectinib at Sun Yat-sen University Cancer Center.

HD Immune GmbH announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman.

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on next-generation antibody therapeutics, announced today the initiation of patient dosing in the Phase 1a/b clinical trial of PMC-309 in patients with advanced or metastatic solid tumors.

Biomerica, Inc. today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to serve as the Chairman of the Board of Directors of Biomerica.

Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer.

Enable Biosciences Inc. is proud to announce the enhancement of its ‘Kit to Clinics’ program for type 1 diabetes care, featuring the ADAP technology, rigorously and exhaustively vetted through multiple peer-reviewed and/or blinded studies.